Biliary Tract Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology

Posted on
by

Biliary Tract Cancer Market to Exhibit Rapid Growth Rate During the Forecast Period (2023-2032), Investigates DelveInsight | Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology
DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Tract Cancer.

DelveInsight’s “Biliary Tract Cancer Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Biliary Tract Cancer, historical and forecasted epidemiology as well as the Biliary Tract Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Biliary Tract Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Biliary Tract Cancer Market Forecast

 

Some of the key facts of the Biliary Tract Cancer Market Report: 

  • The Biliary Tract Cancer market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In June 2023, Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the U.S. Food and Drug Administration (FDA) has accepted for review a new supplemental Biologics Licence Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with standard of care chemotherapy (gemcitabine and cisplatin) for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer (BTC).
  • A total of 37,451 new cases of biliary tract cancer were reported in the 7MM population in 2021. Japan has the highest number of BTC cancer cases, followed by the US
  • In the United States and Japan, respectively, there were 10,317 and 14,218 BTC incident cases in 2021
  • For localised and regional instances, 1L advanced or metastatic cases, and 2L+ advanced or metastatic cases, respectively, there were 68, 935, and 374 treated cases overall in Spain in 2021
  • Key Biliary Tract Cancer Companies: Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Eisai and Merck, SMT bio Co., Ltd., InnoPharmax Inc., Merck KGaA, RemeGen Co., Ltd., Eisai Co., Ltd., Hoffmann-La Roche, Shanghai Miracogen Inc., and others
  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Zanidatamab, Futibatinib (TAS-120), Melphalan, Tasugratinib (E7090), TT-00420, Derazantinib (ARQ-087), Lenvima (lenvatinib), SMT-NK inj.+Pembrolizumab, D07001, M7824, RC48-ADC, Lenvatinib, Atezolizumab, MRG003, and others 
  • The Biliary Tract Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Biliary Tract Cancer pipeline products will significantly revolutionize the Biliary Tract Cancer market dynamics.

 

Biliary Tract Cancer Overview

Hepatocellular carcinoma (HCC), biliary tract cancer (BTC), and other metastatic disorders are examples of prevalent malignant liver lesions. The following are epithelial malignancies of the biliary tree that make up biliary tract carcinoma (BTC): Cholangiocarcinoma (CCA) and gallbladder cancer (GBC). The three types of CCA are intra-hepatic, perihilar (Klatskin’s tumour), and distal.

 

Get a Free sample for the Biliary Tract Cancer Market Report 

https://www.delveinsight.com/report-store/biliary-tract-cancers-btcs-market

 

Biliary Tract Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Biliary Tract Cancer Epidemiology Segmentation:

The Biliary Tract Cancer market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Biliary Tract Cancer
  • Prevalent Cases of Biliary Tract Cancer by severity
  • Gender-specific Prevalence of Biliary Tract Cancer
  • Diagnosed Cases of Episodic and Chronic Biliary Tract Cancer

 

Download the report to understand which factors are driving Biliary Tract Cancer epidemiology trends @ Biliary Tract Cancer Epidemiology Forecast

 

Biliary Tract Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Biliary Tract Cancer market or expected to get launched during the study period. The analysis covers Biliary Tract Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Biliary Tract Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Biliary Tract Cancer Therapies and Key Companies

  • Keytruda (pembrolizumab): Merck
  • Imfinzi (durvalumab): AstraZeneca
  • Zanidatamab: Zymeworks & BeiGene
  • Futibatinib (TAS-120): Taiho Oncology
  • Melphalan: Delcath Systems
  • Tasugratinib (E7090): Eisai
  • TT-00420: TransThera Sciences
  • Derazantinib (ARQ-087): Basilea Pharmaceutica
  • Lenvima (lenvatinib): Eisai and Merck
  • SMT-NK inj.+Pembrolizumab: SMT bio Co., Ltd.
  • D07001: InnoPharmax Inc.
  • M7824: Merck KGaA
  • RC48-ADC: RemeGen Co., Ltd.
  • Lenvatinib: Eisai Co., Ltd.
  • Atezolizumab: Hoffmann-La Roche
  • MRG003: Shanghai Miracogen Inc.

 

Discover more about therapies set to grab major Biliary Tract Cancer market share @ Biliary Tract Cancer Treatment Market

 

Biliary Tract Cancer Market Drivers

  • Identification of novel biomarkers
  • New coding system for CCA
  • Increasing R&D activities

 

Biliary Tract Cancer Market Barriers

  • Lack of specific approach
  • Complex and heterogeneous nature of the disease
  • Development of chemo resistance in cholangiocarcinoma

 

Scope of the Biliary Tract Cancer Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Biliary Tract Cancer Companies: Merck, AstraZeneca, Zymeworks & BeiGene, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences, Basilea Pharmaceutica, Eisai and Merck, SMT bio Co., Ltd., InnoPharmax Inc., Merck KGaA, RemeGen Co., Ltd., Eisai Co., Ltd., Hoffmann-La Roche, Shanghai Miracogen Inc., and others
  • Key Biliary Tract Cancer Therapies: Keytruda (pembrolizumab), Imfinzi (durvalumab), Zanidatamab, Futibatinib (TAS-120), Melphalan, Tasugratinib (E7090), TT-00420, Derazantinib (ARQ-087), Lenvima (lenvatinib), SMT-NK inj.+Pembrolizumab, D07001, M7824, RC48-ADC, Lenvatinib, Atezolizumab, MRG003, and others
  • Biliary Tract Cancer Therapeutic Assessment: Biliary Tract Cancer current marketed and Biliary Tract Cancer emerging therapies
  • Biliary Tract Cancer Market Dynamics: Biliary Tract Cancer market drivers and Biliary Tract Cancer market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Biliary Tract Cancer Unmet Needs, KOL’s views, Analyst’s views, Biliary Tract Cancer Market Access and Reimbursement 

 

To know more about Biliary Tract Cancer companies working in the treatment market, visit @ Biliary Tract Cancer Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Biliary Tract Cancer Market Report Introduction

2. Executive Summary for Biliary Tract Cancer

3. SWOT analysis of Biliary Tract Cancer

4. Biliary Tract Cancer Patient Share (%) Overview at a Glance

5. Biliary Tract Cancer Market Overview at a Glance

6. Biliary Tract Cancer Disease Background and Overview

7. Biliary Tract Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Biliary Tract Cancer 

9. Biliary Tract Cancer Current Treatment and Medical Practices

10. Biliary Tract Cancer Unmet Needs

11. Biliary Tract Cancer Emerging Therapies

12. Biliary Tract Cancer Market Outlook

13. Country-Wise Biliary Tract Cancer Market Analysis (2019–2032)

14. Biliary Tract Cancer Market Access and Reimbursement of Therapies

15. Biliary Tract Cancer Market Drivers

16. Biliary Tract Cancer Market Barriers

17.  Biliary Tract Cancer Appendix

18. Biliary Tract Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services